Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Early diagnosis of neonatal cholestatic jaundice

Test at 2 weeks

Eric I. Benchimol, Catharine M. Walsh and Simon C. Ling
Canadian Family Physician December 2009, 55 (12) 1184-1192;
Eric I. Benchimol
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catharine M. Walsh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon C. Ling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: simon.ling@sickkids.ca
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE To review best practices for early recognition and treatment of conditions resulting in neonatal cholestasis, in order to improve long-term outcomes for affected infants.

QUALITY OF EVIDENCE Studies, review articles, and meta-analyses pertaining to neonatal-onset cholestasis were sought via electronic databases. Reference lists of studies and review articles supplemented the electronic search. Studies were included if they examined the importance of early diagnosis and intervention for cholestatic jaundice of any cause, and mainly comprised Level II and Level III evidence.

MAIN MESSAGE Review of the relevant literature supports the recommendation that infants with jaundice at 2 weeks of age should be tested for cholestasis by quantifying the direct reacting bilirubin levels in their blood. Subsequent rapid investigation using a diagnostic algorithm enables early diagnosis of the specific cause and facilitates timely intervention for conditions whose outcomes are improved by early treatment.

CONCLUSION Universal screening for neonatal cholestasis might help with early identification of cases and improve outcomes, although further study is required in the North American setting.

Friends, family, and health care workers often reassure parents that their infants’ jaundice is normal, requires neither investigation nor treatment, and will resolve without adverse consequences. Unfortunately, misdiagnosis of cholestasis (Box 11) as physiologic jaundice delays the identification of important liver disease and substantially impairs long-term health. We have conducted a review of the literature to summarize the evidence for early identification and intervention in biliary atresia and other forms of cholestatic jaundice. In response to an observed pattern of late referral of infants with cholestasis, we aim to provide primary care physicians with evidence of the benefits of early identification, reinforcing the need to test for the condition at 2 to 3 weeks of age in jaundiced infants, and to provide an approach to investigation.

Box 1

Indicators of cholestasis

  • Direct reacting serum bilirubin levels > 17 μmol/L (1.0 mg/dL)

  • Direct reacting bilirubin > 20% of the total serum bilirubin concentration, if total bilirubin is >85 μmol/L (5.0 mg/dL)

Up to 15% of breastfed infants experience jaundice lasting more than 3 weeks2; meanwhile, neonatal cholestasis occurs in 0.04% to 0.2% of live births.1,3 Cholestasis and direct reacting hyperbilirubinemia arise from abnormalities in the uptake, handling, transport, and excretion of bile salts and bilirubin by hepatocytes or in the flow of bile through the bile canaliculi and ducts.4 A detailed description of the molecular mechanisms of cholestasis is beyond the scope of this review, but is available in a recent article by Trauner et al.4 Of the many conditions that can present with neonatal cholestasis (Table 15), biliary atresia and idiopathic neonatal hepatitis are the most common; in a study of affected infants presenting to King’s College Hospital in London, England, these conditions accounted for 35% and 30% of cases, respectively.6 Other common causes included α1-antitrypsin deficiency (17%), Alagille syndrome (6%), and choledochal cysts (3%).6 New diagnostic techniques have decreased the number of infants diagnosed with idiopathic hepatitis in favour of previously under-reported conditions, such as progressive familial intrahepatic cholestasis, storage disorders, mitochondrial disorders, and bile acid synthetic defects.7

View this table:
  • View inline
  • View popup
Table 1

Differential diagnoses and diagnostic approaches for infants with cholestasis

A recent retrospective cohort study from the Canadian Pediatric Hepatology Research Group (CPHRG) estimated the incidence of biliary atresia in Canada to be 1 in 19 065 (5.25 per 100 000 live births).8 Approximately 60% to 70% of patients with biliary atresia will develop cirrhosis and require liver transplantation in childhood,8,9 half within the first 2 years of life.10 Biliary atresia is the most common single indication for liver transplantation in children.11,12

The CPHRG reported that 14% of Canadian infants with jaundice caused by biliary atresia presented to tertiary referral centres after the age of 3 months. However, multiple cohort studies have reported that infants surgically treated for biliary atresia before 3 months of age had improved overall survival at up to 15 years of age.8,13,14 In 2 studies that examined the reasons for late referral of infants with cholestatic jaundice,6,15 most involved either inadequate follow-up of neonatal jaundice or reassurances by primary health care providers that the jaundice was physiologic; however, both are preventable causes of delay.

Quality of evidence

All studies, review articles, and meta-analyses pertaining to neonatal-onset cholestasis were identified by a search of electronic databases, including MEDLINE (from January 1950 to October 2008); EMBASE (January 1980 to October 2008); OVID Evidence-Based Medicine Reviews databases (eg, the Cochrane Database of Systematic Reviews, the ACP Journal Club, the Database of Abstracts of Reviews of Effectiveness, the Cochrane Central Register of Controlled Trials, the Cochrane Methology Register, Health Technology Assessment, and the National Health Service Economic Evaluation Database, from January 1991 to July 2008); and the Cochrane Methodology Register (until July 2008). Search terms included cholestasis, jaundice and conjugated, mass screening, biliary atresia, galactosemia, tyrosinemia, congenital hypothyroidism, cystic fibrosis, Kasai, and hepatoportoenterostomy, with randomized controlled trial, controlled clinical trial, systematic review, cohort study, guideline, diagnosis, and early diagnosis. These terms were searched by subject heading and key word. Search terms were combined using Boolean logic, while studies, publications, and guidelines included in this review were limited to the neonatal population (< 60 days old) and were directed toward ascertaining the importance of early diagnosis and mass screening for neonatal cholestatic conditions.

Reference lists of studies and review articles supplemented the electronic search. Studies were included if they examined the importance of early diagnosis and intervention for cholestatic jaundice, of any cause.

Evaluation of neonatal cholestasis

Total and direct reacting serum bilirubin levels must be measured in any infant who is still jaundiced at 2 to 3 weeks of age, according to recommendations from the Canadian Paediatric Society,16 the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition,1 and the American Academy of Pediatrics.17 Early detection is essential to facilitate timely intervention and minimize adverse outcomes in several conditions, including biliary atresia, hypothyroidism, and galactosemia. It is important to note that infants with biliary atresia might not necessarily present with typical symptoms of failure to thrive or ascites,15 and the primary care physician must be suspicious of cholestasis in all cases of prolonged jaundice.

Any infant with cholestatic jaundice or liver disease should be immediately referred to a pediatric gastroenterologist. The differential diagnosis of cholestatic jaundice is extensive and its evaluation demands a systematic approach. A clinical practice guideline for the investigation of cholestatic jaundice has recently been composed by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition,1 with an algorithm to guide the investigation of infants with cholestatic jaundice Figure 11,17). A detailed history and physical examination can provide clues to diagnosis. Pale, acholic stools suggest an obstructive process such as biliary atresia; deeply pigmented stools usually rule this out. Medical practitioners should directly observe the stool, as parental reports might overestimate the degree of pigmentation.18 Urine colour is less useful as a sign of neonatal cholestasis. The urine of a normal newborn is usually colourless; however, although yellow urine should raise suspicion in a jaundiced infant, the absence of dark urine does not rule out disease and further testing is warranted.1 Liver function should be established by determining albumin levels, the international normalized ratio (for anticoagulant monitoring), serum ammonia, and blood glucose levels. Concentrations of alanine aminotransferase and aspartate aminotransferase further evaluate the extent of hepatocellular injury, and elevated γ-glutamyltransferase and alkaline phosphatase levels indicate possible obstructive causes of cholestasis. Liver enzyme concentrations are poor predictors of etiology (sensitivity 68%, specificity 43% for the diagnosis of biliary atresia),19 but might provide useful information in combination with clinical evaluation to guide further investigation.

Figure 1
  • Download figure
  • Open in new tab
Figure 1

Algorithm for investigation of the neonate with cholestatic jaundice

Imaging via abdominal ultrasound can help diagnose biliary sludging, inspissated bile, or gallstones and discern structural abnormalities, such as choledochal cysts. A small or absent gallbladder on hepatic ultrasound suggests biliary atresia, but a sensitivity as low as 23% in a recent prospective study indicates that ultrasound cannot be used to rule out this diagnosis.20 Studies found that the “triangular cord” sign, identified at the porta hepatis during ultrasound and probably representing fibrosis at the portal plate, was 73% to 100% sensitive and 98% to 100% specific for the diagnosis of biliary atresia. The range of sensitivities might have been due to study design or operator experience.19,21,22 Additionally, polysplenia and situs inversus are associated with biliary atresia.1 Hepatic ultrasound is best performed at a centre with pediatric radiologic expertise, as its accuracy is operator-dependent.

Hepatobiliary scintigraphy is helpful in distinguishing obstructive from nonobstructive cases of cholestasis. Uptake of the tracker by hepatocytes should be followed by its excretion in bile into the intestine within 24 hours; absence of this excretion is an abnormal result that indicates biliary obstruction or severe hepatocellular dysfunction.23 The sensitivity of scintigraphy for the diagnosis of biliary atresia was demonstrated to be high in 2 retrospective studies (83% to 100%, respectively), with virtually all affected patients showing no excretion, but specificity was considerably lower, ranging from 33% to 80%.24,25 Rarely, bile drainage is initially present in infants with cholestatis disease but is subsequently lost after 2 to 3 weeks of age; therefore, early scintigraphy might be misleading. Pretreatment with phenobarbital (5 mg/kg/d) for 5 days before the study was shown to enhance test precision in one study,26 while another found improved specificity with ursodeoxycholic acid (5 mg/kg twice daily).27

Recent expansion of newborn screening programs in certain jurisdictions has improved the amount of information available to primary care providers investigating neonatal jaundice. Results of newborn screening tests should be verified by further testing of all infants with cholestatic jaundice. Although review of the diagnostic accuracy of all investigations for neonatal cholestasis is beyond the scope of this article, an extensive list of investigations is provided in Table 1.5

Management and outcome of biliary atresia

Biliary atresia is uniformly fatal within 1 to 2 years if left untreated. Initial management is surgical (portoenterostomy, or Kasai operation), entailing excision of the atretic biliary tree and fibrous plate and Roux-en-Y anastomosis of jejunum to the remaining ducts to allow for biliary drainage.28 European and North American studies have revealed medium-term survival rates (2 to 10 years’ follow-up) without liver transplantation in 25% to 60% of patients who underwent portoenterostomy.13,23,29,30 The Canadian experience with biliary atresia shows a 10-year overall survival rate of 77% after portoenterostomy and native liver survival rates of 46% at 2 years, 36% at 4 years, and 26% at 10 years.8 Any intervention that improves native liver and overall survival rates could affect the quality of life of these children as well as the availability of transplant organs.

Importance of early diagnosis

The outcome of patients with biliary atresia is directly affected by the speed with which health care providers arrive at the diagnosis. The CPHRG recently discovered that 10-year native liver survival rates declined with increasing age at the time of portoenterostomy; 49% of infants who underwent surgery in Canada at 30 days of age were living with their own liver 10 years later, compared with 25% of those whose operations occurred at 31 to 90 days of age and 15% of those treated after 90 days of age.8 This finding is consistent with other studies,9 although an American retrospective cohort study was unable to demonstrate whether age at the time of portoenterostomy affected native liver survival, likely owing to small numbers of study subjects and a short (2 year) follow-up.10 A recent study from France demonstrated the benefit of earlier intervention—15-year survival with native liver.14 The consensus that younger age at the time of portoenterostomy leads to improved outcomes has led professional organizations to recommend measurement of direct reacting bilirubin levels in infants with persisting jaundice at 2 to 3 weeks of age.2,16

One barrier to early identification of cholestatic jaundice might be the schedules for newborn infant assessment commonly followed by health care providers. According to the Rourke Baby Record,31 endorsed by the Canadian Paediatric Society and the College of Family Physicians of Canada, visits at 2 weeks and 1 month of age are considered “optional”; measurement of direct reacting bilirubin serum levels is not mentioned. The American Academy of Pediatrics’ Recommendations for Preventive Pediatric Health Care32 contain no mention of assessment for cholestasis at the 1-month visit.

The natural history of many other conditions that present with neonatal cholestasis can also be altered by early medical intervention. In patients with congenital hypothyroidism, 2 retrospective cohort studies demonstrated the importance of early (< 2 weeks of age) intervention with high-dose (10 to 15 μg/kg/d) levothyroxine in improving neurodevelopmental outcomes.33,34 In symptomatic patients with congenital cytomegalovirus infection and multiorgan involvement, timely introduction of ganciclovir reduces the prevalence of congenital hearing loss,35 although criteria for selection of candidates for treatment are controversial, and consultation with an infectious disease specialist is necessary. Dietary treatment of galactosemia improves outcomes of affected infants, although mental retardation and other neurologic abnormalities are still occasionally seen in patients adherent to treatment.36 Treatment of tyrosinemia with nitisinone and a diet low in tyrosine, phenylalanine, and methionine reduces the risk of developmental delay, cardiomyopathy, hepatic failure, and hepatocellular carcinoma; however, patients should still be screened regularly for the development of liver masses.37,38

Screening for cholestatic jaundice

Screening tests represent a unique opportunity to detect neonatal cholestasis at an early age. Biliary atresia fulfils criteria of a condition considered appropriate for universal newborn screening; it is an important health problem with a latent or early symptomatic period during which timely intervention will improve outcomes.39 Therefore, investigators have studied the feasibility and efficacy of various screening methods.

Persistently pale stools are found in up to 95% of infants with biliary atresia.40 Screening of newborns for biliary atresia using stool colour cards was initiated in Japan in the early 1990s.18,41 Parents compared their infants’ stool colours with 7 shades printed on a “stool colour card” and notified their doctors of the results at the routine 1-month health visit. The sensitivity and specificity of the screening program in Japan were 67% and 99.9%, respectively.42 The average age at the time of portoenterostomy was reduced to 53 days (range 40 to 109 days) in the screened group, compared with an average age of 84 days (range 25 to 138 days) for children not screened. Introduction of a similar nationwide screening program in Taiwan43 coincided with an increased proportion of infants undergoing portoenterostomy before 60 days of age (74.3% in 2005, compared with historical rates of 23% from 1976 to 1989 and 36% from 1976 to 2000).43–45 The sensitivity and specificity of stool colour card screening tests in Taiwan were 72% to 97% and 99.9%, respectively.45

Several studies have been carried out to investigate the utility of serum and urine bile acid measurements as screening modalities for cholestasis and biliary atresia; however, pathological elevations might not be present until 2 to 4 weeks of age, and the pattern of bile acid elevations in biliary atresia is indistinguishable from other causes of cholestatic liver disease.46–49 New technologies (eg, genomics, proteomics) might have the potential to identify novel serum and urine biomarkers of biliary atresia, which would be useful in future screening initiatives.

Conclusion

Table 2 summarizes the strategies to improve outcomes of infants with cholestatic jaundice. Early identification of cholestatic jaundice to enable optimal timing of medical and surgical management can be achieved through universal assessment of infants at 2 weeks of age, measurement of direct reacting bilirubin in any that appear jaundiced, and immediate referral to pediatric liver services if cholestasis is identified. Biliary atresia fulfils the criteria for a condition considered to be appropriate for a universal screening program, the implementation of which would have the potential to improve outcomes through enhanced early detection. The availability of a reliable and convenient screening test remains a challenge, although the use of stool colour cards seems promising and should be investigated further. In the meantime, health care workers, including family practitioners and pediatricians, should adopt a “test at 2 weeks” strategy to ensure that we are doing everything possible to positively affect the outcomes of infants with cholestatic jaundice.

View this table:
  • View inline
  • View popup
Table 2

Summary of recommendations and evidence base for strategies to improve outcome of patients with neonatal cholestasis

Levels of evidence

Level I: At least one properly conducted randomized controlled trial, systematic review, or meta-analysis

Level II: Other comparison trials, non-randomized, cohort, case-control, or epidemiologic studies, and preferably more than one study

Level III: Expert opinion or consensus statements

Acknowledgment

We thank Dr Orlee Guttman and Ms Constance O’Connor for their review of the manuscript and editorial suggestions. We also thank Dr Vicky Ng and Dr Eve Roberts for their guidance and content expertise. Dr Benchimol is a Canadian Institutes of Health Research training fellow in the Canadian Child Health Clinician Scientist Program (CCHCSP), in partnership with the SickKids Foundation and the Child and Family Research Institute of British Columbia, and was also supported by fellowships from the Children’s Digestive Health and Nutrition Foundation of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the Clinician Scientist Training Program at the Hospital for Sick Children in Toronto, Ont. Dr Walsh is supported by a fellowship from the Royal College of Physicians and Surgeons of Canada and a career enhancement award from the CCHCSP.

Notes

EDITOR’S KEY POINTS

  • Many societies recommend measuring total and direct reacting serum bilirubin levels in any infant who is still jaundiced at 2 to 3 weeks of age; however, 14% of Canadian infants with biliary atresia were referred for portoenterostomy only after 3 months of age.

  • The main reason for late referral of infants with cholestatic jaundice is either inadequate follow-up of neonatal jaundice or reassurances by primary health care providers that the jaundice is physiologic; further, the schedules for newborn infant assessment commonly followed by health care providers might be a contributing factor.

  • Early identification of cholestatic jaundice to enable optimal timing of medical and surgical management can be achieved through universal assessment of infants at 2 weeks of age, measurement of direct reacting bilirubin levels in any who appear jaundiced, and immediate referral to pediatric liver services if cholestasia is identified.

POINTS DE REPÈRE DU RÉDACTEUR

  • De nombreuses sociétés recommandent de mesurer les niveaux de bilirubine totale et conjuguée chez tout nourrisson qui est encore ictérique 2 à 3 semaines après la naissance; pourtant, 14 % des nourrissons nés avec une atrésie biliaire étaient âgés d’au moins 3 mois lorsqu’ils ont été dirigés pour une portoentérostomie.

  • La principale raison pour retarder le transfert des nourrissons qui ont un ictère cholestatique est le suivi inadéquat d’un ictère néonatal ou l’assurance donnée par les soignants de première ligne que l’ictère est « physiologique »; ajoutons que le calendrier généralement utilisé par les soignants de première ligne pour l’évaluation des nouveau-nés pourrait aussi être en cause.

  • On peut faire la détection précoce de l’ictère cholestatique et permettre une chronologie optimale pour le traitement médical et chirurgical en pratiquant une évaluation systématique des nourrissons à 2 semaines, un dosage de la bilirubine conjuguée chez tous ceux qui semblent ictériques et un transfert immédiat vers un département d’hépatologie pédiatrique dès qu’une cholestase est confirmée.

Footnotes

  • Contributors

    Drs Benchimol, Walsh, and Ling contributed to the literature search and the preparation of the article for submission.

  • Competing interests

    None declared

  • Cet article a fait l’objet d’une révision par des pairs.

  • This article has been peer reviewed.

  • Data from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.1

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    MoyerVFreeseDKWhitingtonPFOlsonADBrewerFCollettiRBGuideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and NutritionJ Pediatr Gastroenterol Nutr200439211528Erratum in: J Pediatr Gastroenterol Nutr 2004:39(3):306
    OpenUrlCrossRefPubMed
  2. ↵
    WinfieldCRMacFaulRClinical study of prolonged jaundice in breast- and bottle-fed babiesArch Dis Child19785365067
    OpenUrlAbstract/FREE Full Text
  3. ↵
    MushtaqILoganSMorrisMJohnsonAWWadeAMKellyDScreening of newborn infants for cholestatic hepatobiliary disease with tandem mass spectrometryBMJ199931972084717Erratum in: BMJ 1999;319(7219)1253
    OpenUrlAbstract/FREE Full Text
  4. ↵
    TraunerMMeierPJBoyerJLMolecular pathogenesis of cholestasisN Engl J Med199833917121727
    OpenUrlCrossRefPubMed
  5. ↵
    WalshCMSimpsonEAZachosMDipchandAIFriedmanJNBismillaZGuptaSLamCGastroenterology and hepatologyThe Hospital for Sick Children handbook of pediatrics11th edToronto, ONElsevier Canada20093389
  6. ↵
    Mieli-VerganiGHowardERPortmanBMowatAPLate referral for biliary atresia—missed opportunities for effective surgeryLancet1989186354213
    OpenUrlCrossRefPubMed
  7. ↵
    SuchyFJSuchyFJSokolRJBalistreriWFApproach to the infant with cholestasisLiver disease in children3rd edNew York, NYCambridge University Press200717989
  8. ↵
    SchreiberRABarkerCCRobertsEAMartinSRAlvarezFSmithLBiliary atresia: the Canadian experienceJ Pediatr 2007151665965665.e1Epub 2007 Oct 22
    OpenUrlPubMed
  9. ↵
    SokolRJShepherdRWSuperinaRBezerraJARobuckPHoofnagleJHScreening and outcomes in biliary atresia: summary of a National Institutes of Health workshopHepatology200746256681
    OpenUrlCrossRefPubMed
  10. ↵
    ShneiderBLBrownMBHaberBWhitingtonPFSchwarzKSquiresRA multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000J Pediatr2006148446774
    OpenUrlCrossRefPubMed
  11. ↵
    MartinSRAtkisonPAnandRLindbladASSPLIT Research GroupStudies of Pediatric Liver Transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and CanadaPediatr Transplant20048327383
    OpenUrlPubMed
  12. ↵
    D’AlessandroAMKnechtleSJChinLTFernandezLAYagciGLeversonGLiver transplantation in pediatric patients: twenty years of experience at the University of WisconsinPediatr Transplant200711666170
    OpenUrlPubMed
  13. ↵
    ChardotCCartonMSpire-BendelacNLe PommeletCGolmardJLAuvertBEpidemiology of biliary atresia in France: a national study 1986–96J Hepatol1999316100613
    OpenUrlCrossRefPubMed
  14. ↵
    SerinetMOWildhaberBEBrouéPLachauxASarlesJJacqueminEImpact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screeningPediatrics2009123512806
    OpenUrlAbstract/FREE Full Text
  15. ↵
    LeeWSPre-admission consultation and late referral in infants with neonatal cholestasisJ Paediatr Child Health2008441–25761Epub 2007 Jul 19
    OpenUrlPubMed
  16. ↵
    Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks’ gestation)—summaryPaediatr Child Health200712540118
    OpenUrlPubMed
  17. ↵
    American Academy of Pediatrics Subcommittee on HyperbilirubinemiaManagement of hyperbilirubinemia in the newborn infant 35 or more weeks of gestationPediatrics20041141297316Erratum in: Pediatrics 2004;114(4):1138
    OpenUrlAbstract/FREE Full Text
  18. ↵
    MatsuiAIshikawaTIdentification of infants with biliary atresia in JapanLancet19943438902925
    OpenUrlPubMed
  19. ↵
    DehghaniSMHaghighatMImaniehMHGeramizadehBComparison of different diagnostic methods in infants with cholestasisWorld J Gastroenterol2006123658936
    OpenUrlPubMed
  20. ↵
    HumphreyTMStringerMDBiliary atresia: US diagnosisRadiology2007244384551
    OpenUrlCrossRefPubMed
  21. ↵
    LeeHJLeeSMParkWHChoiSOObjective criteria of triangular cord sign in biliary atresia on US scansRadiology20032292395400
    OpenUrlPubMed
  22. ↵
    TakamizawaSZaimaAMurajiTKanegawaKAkasakaYSatohSCan biliary atresia be diagnosed by ultrasonography alone?J Pediatr Surg2007421220936
    OpenUrlCrossRefPubMed
  23. ↵
    McKiernanPJBakerAJKellyDAThe frequency and outcome of biliary atresia in the UK and IrelandLancet20003559197259
    OpenUrlCrossRefPubMed
  24. ↵
    EsmailiJIzadyarSKaregarIGholamrezanezhadABiliary atresia in infants with prolonged cholestatic jaundice: diagnostic accuracy of hepatobiliary scintigraphyAbdom Imaging 20073222437Epub 2006 Sep 12
    OpenUrlCrossRefPubMed
  25. ↵
    GilmourSMHershkopMReifenRGildayDRobertsEAOutcome of hepatobiliary scanning in neonatal hepatitis syndromeJ Nucl Med1997388127982
    OpenUrlAbstract/FREE Full Text
  26. ↵
    CharearnradPChongsrisawatVTepmongkolSPoovorawanYThe effect of phenobarbital on the accuracy of technetium-99m diisopropyl iminodiacetic acid hepatobiliary scintigraphy in differentiating biliary atresia from neonatal hepatitis syndromeJ Med Assoc Thai200386Suppl 2S18994
    OpenUrlPubMed
  27. ↵
    PoddarUBhattacharyaAThapaBRMittalBRSinghKUrsodeoxycholic acid-augmented hepatobiliary scintigraphy in the evaluation of neonatal jaundiceJ Nucl Med2004459148892
    OpenUrlAbstract/FREE Full Text
  28. ↵
    OhiRSurgery for biliary atresiaLiver200121317582
    OpenUrlCrossRefPubMed
  29. ↵
    NioMOhiRMiyanoTSaekiMShirakiKTanakaKFive- and 10-year survival rates after surgery for biliary atresia: a report from the Japanese Biliary Atresia RegistryJ Pediatr Surg20033879971000
    OpenUrlCrossRefPubMed
  30. ↵
    YoonPWBreseeJSOlneyRSJamesLMKhouryMJEpidemiology of biliary atresia: a population-based studyPediatrics199799337682
    OpenUrlAbstract/FREE Full Text
  31. ↵
    RourkeLLeducDRourkeJConstantinEHealth supervision from 0 to 5 years using the Rourke Baby Record 2006Can Fam Physician20065212734
    OpenUrlFREE Full Text
  32. ↵
    American Academy of PediatricsRecommendations for preventive pediatric health carePediatrics200712061376Available from: http://aappolicy.aappublications.org/cgi/content/full/pediatrics;105/3/645Accessed 2009 Nov 2
    OpenUrlFREE Full Text
  33. ↵
    Bongers-SchokkingJJKootHMWiersmaDVerkerkPHde Muinck Keizer-SchramaSMInfluence of timing and dose of thyroid hormone replacement on development in infants with congenital hypothyroidismJ Pediatr200013632927
    OpenUrlCrossRefPubMed
  34. ↵
    Bongers-SchokkingJJde Muinck Keizer-SchramaSMInfluence of timing and dose of thyroid hormone replacement on mental, psychomotor, and behavioral development in children with congenital hypothyroidismJ Pediatr2005147676874
    OpenUrlCrossRefPubMed
  35. ↵
    KimberlinDWLinCYSánchezPJDemmlerGJDanknerWSheltonMEffect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trialJ Pediatr200314311625
    OpenUrlCrossRefPubMed
  36. ↵
    BoschAMClassical galactosaemia revisitedJ Inherit Metab Dis 200629451625Epub 2006 Jul 11
    OpenUrlCrossRefPubMed
  37. ↵
    McKiernanPJNitisinone in the treatment of hereditary tyrosinaemia type 1Drugs200666674350
    OpenUrlCrossRefPubMed
  38. ↵
    MitchellGARezvaniIKliegmanRMBehrmanREJensonHBStantonBMDTyrosineNelson textbook of pediatrics18th edPhiladelphia, PAWB Saunders Co20075326
  39. ↵
    Newborn screening: toward a uniform screening panel and systemGenet Med20068Suppl 11S252S
    OpenUrlCrossRefPubMed
  40. ↵
    LaiMWChangMHHsuSCHsuHCSuCTKaoCLDifferential diagnosis of extrahepatic biliary atresia from neonatal hepatitis: a prospective studyJ Pediatr Gastroenterol Nutr19941821217
    OpenUrlPubMed
  41. ↵
    MatsuiADodorikiMScreening for biliary atresiaLancet199534589581181
    OpenUrlPubMed
  42. ↵
    MakiTSumazakiRMatsuiAMass screening for biliary atresiaJpn J Pediatr Surg1999312426
    OpenUrl
  43. ↵
    ChenSMChangMHDuJCLinCCChenACLeeHCScreening for biliary atresia by infant stool color card in TaiwanPediatrics20061174114754
    OpenUrlAbstract/FREE Full Text
  44. HungPYChenCCChenWJLaiHSHsuWMLeePHLong-term prognosis of patients with biliary atresia: a 25 year summaryJ Pediatr Gastroenterol Nutr20064221905
    OpenUrlCrossRefPubMed
  45. ↵
    HsiaoCHChangMHChenHLLeeHCWuTCLinCCUniversal screening for biliary atresia using an infant stool color card in TaiwanHepatology2008474123340
    OpenUrlCrossRefPubMed
  46. ↵
    BalistreriWFSuchyFJFarrellMKHeubiJEPathologic versus physiologic cholestasis: elevated serum concentration of a secondary bile acid in the presence of hepatobiliary diseaseJ Pediatr1981983399402
    OpenUrlCrossRefPubMed
  47. JavittNBKeatingJPGrandRJHarrisRCSerum bile acid patterns in neonatal hepatitis and extrahepatic biliary atresiaJ Pediatr19779057369
    OpenUrlCrossRefPubMed
  48. TazawaYYamadaMNakagawaMKonnoTTadaKSerum bile acid patterns determined by an enzymatic method and high-performance liquid chromatography in young infants with cholestasisJ Pediatr Gastroenterol Nutr198433394401
    OpenUrlPubMed
  49. ↵
    YousefIMPerwaizSLamireauTTuchweberBUrinary bile acid profile in children with inborn errors of bile acid metabolism and chronic cholestasis; screening technique using electrospray tandem mass-spectrometry (ES/MS/MS)Med Sci Monit 200393MT2131
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top

In this issue

Canadian Family Physician: 55 (12)
Canadian Family Physician
Vol. 55, Issue 12
1 Dec 2009
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Early diagnosis of neonatal cholestatic jaundice
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Early diagnosis of neonatal cholestatic jaundice
Eric I. Benchimol, Catharine M. Walsh, Simon C. Ling
Canadian Family Physician Dec 2009, 55 (12) 1184-1192;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Early diagnosis of neonatal cholestatic jaundice
Eric I. Benchimol, Catharine M. Walsh, Simon C. Ling
Canadian Family Physician Dec 2009, 55 (12) 1184-1192;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Quality of evidence
    • Evaluation of neonatal cholestasis
    • Management and outcome of biliary atresia
    • Importance of early diagnosis
    • Screening for cholestatic jaundice
    • Conclusion
    • Levels of evidence
    • Acknowledgment
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Depistage de latresie des voies biliaires : cest dans les cartes
  • Screening for biliary atresia: its in the cards
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Clinical Review

  • Buprenorphine-naloxone microdosing
  • Approach to hearing loss
  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
Show more Clinical Review

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2021 by The College of Family Physicians of Canada

Powered by HighWire